Precigen Q1 revenue beats estimates on PAPZIMEOS launch

Precigen

13/05/2026 21:17

Overview

U.S. biopharmaceutical firm's Q1 revenue surged, beating analyst expectations on PAPZIMEOS launch

Net loss for Q1 narrowed sharply compared to prior-year period

Company expects cash and PAPZIMEOS sales to fund operations through break-even by the end of 2026

Outlook

Company expects cash and anticipated PAPZIMEOS revenue to fund operations to cash flow break-even by end-2026

Precigen plans to provide an AdenoVerse pipeline update, including PRGN-2009, by end of year

Marketing Authorization Application for PAPZIMEOS under review by EMA; decision pending

Result Drivers

PAPZIMEOS LAUNCH - Q1 revenue growth driven by commercial launch of PAPZIMEOS following FDA approval in August 2025

BROAD UPTAKE - PAPZIMEOS prescriptions spanned both major medical centers and community practices, reflecting broad-based demand

PATIENT ACCESS AND PAYER COVERAGE - Permanent J-code and broad payer coverage expected to accelerate site activations and facilitate patient access

Company press release: ID:nPnbQpMwHa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$23.25 mln
$20.80 mln (3 Analysts)
Q1 Net Income
-$7.93 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Precigen Inc is $9.50, about 132.8% above its May 12 closing price of $4.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)